Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
November 08, 2023 16:11 ET
|
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results
Epilepsy Drugs Market Size Worth $10.70 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
November 08, 2023 08:45 ET
|
The Insight Partners
Pune, India, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Epilepsy is a neurological condition that can cause seizures and affects millions of people globally. Epilepsy drugs are also known as anti-epileptic...
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 07, 2023 07:00 ET
|
Praxis Precision Medicines, Inc.
Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing...
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
November 02, 2023 10:37 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Epilepsy Therapeutics Market Predicted to Reach USD 14.9 Bn by 2031 | Exclusive Report by Transparency Market Research
October 30, 2023 17:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global epilepsy therapeutics market is projected to surpass US$ 14.9 Bn by 2031,...
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
October 30, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
October 19, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Neurona Therapeutics Completes Clinical Enrollment of First Cohort and Updates on Long-lasting Impact in First Patients Treated in Ongoing Phase I/II Trial of NRTX-1001 Cell Therapy for Drug-resistant Focal Epilepsy
October 19, 2023 08:00 ET
|
Neurona Therapeutics
First cohort treated in Ph I/II clinical trial of NRTX-1001 in adults with focal epilepsy, update on first patients'progress
Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
October 16, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that...
Brain Implants Market to hit USD 10 billion by 2032, says Global Market Insights Inc.
September 10, 2023 19:30 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Sept. 10, 2023 (GLOBE NEWSWIRE) -- Brain Implants Market size is expected to be worth USD 10 billion by 2032. The growing burden of neurological disorders along with the...